Ergomed logo

ERGO - Ergomed Share Price

852p 2.0  0.2%

Last Trade - 25/11/20

Mid Cap
Market Cap £415.1m
Enterprise Value £407.0m
Revenue £73.5m
Position in Universe 592nd / 1803
Unlock ERGO Revenue
Relative Strength (%)
1m -6.38%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -0.93%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
21.2 30.2 39.2 47.6 54.1 68.3 84.8 96.8 +26.4%
-45.3 +48.4 -63.4 +62.4 +13.8
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Ergomed PLCrevenues increased 15% to £40.4M. Net income increased 19%to £4.3M. Revenues reflect Revenue Sales of Goods &Services increase of 62% to £26.1M. Net income benefitedfrom Other operating income increase from £19K to £704K(income), Research & Development decrease of 68% to £99K(expense), Depreciation & Amortization in Selling decreaseof 10% to £608K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ERGO
Graphical History


ERGO Revenue Unlock ERGO Revenue

Net Income

ERGO Net Income Unlock ERGO Revenue

Normalised EPS

ERGO Normalised EPS Unlock ERGO Revenue

PE Ratio Range

ERGO PE Ratio Range Unlock ERGO Revenue

Dividend Yield Range

ERGO Dividend Yield Range Unlock ERGO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ERGO EPS Forecasts Unlock ERGO Revenue
Profile Summary

Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services. It is focused on oncology, neurology and immunology, and the development of orphan drugs. It has two businesses: Services Business and Co-Development Business. The Services Business is a clinical research business providing services to the pharmaceutical and biotechnology industry. The Co-Development Business is a portfolio of partnerships with pharmaceutical and biotechnology companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including out licensing milestones, as well as sales of the product. It provides clinical development, trial management and pharmacovigilance services to over 100 clients.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated September 29, 2000
Public Since July 15, 2014
No. of Shareholders: n/a
No. of Employees: 775
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share , FTSE Aim 100 ,
Exchange London Stock Exchange (AIM)
Shares in Issue 48,717,776
Free Float (0.0%)
Eligible for
ERGO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ERGO
Upcoming Events for ERGO
Frequently Asked Questions for Ergomed
What is the Ergomed share price?

As of 25/11/20, shares in Ergomed are trading at 852p, giving the company a market capitalisation of £415.1m. This share price information is delayed by 15 minutes.

How has the Ergomed share price performed this year?

Shares in Ergomed are currently trading at 852p and the price has moved by 0.135k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Ergomed price has moved by 0.165k% over the past year.

What are the analyst and broker recommendations for Ergomed?

Of the analysts with advisory recommendations for Ergomed, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Ergomed is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Ergomed next release its financial results?

Ergomed is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Ergomed dividend yield?

Ergomed does not currently pay a dividend.

Does Ergomed pay a dividend?

Ergomed does not currently pay a dividend.

When does Ergomed next pay dividends?

Ergomed does not currently pay a dividend.

How do I buy Ergomed shares?

To buy shares in Ergomed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Ergomed?

Shares in Ergomed are currently trading at 852p, giving the company a market capitalisation of £415.1m.

Where are Ergomed shares listed? Where are Ergomed shares listed?

Here are the trading details for Ergomed:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: ERGO
What kind of share is Ergomed?

Based on an overall assessment of its quality, value and momentum, Ergomed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Ergomed share price forecast 2020?

Shares in Ergomed are currently priced at 852p. At that level they are trading at 29.11% discount to the analyst consensus target price of 1,201.86.

Analysts covering Ergomed currently have a consensus Earnings Per Share (EPS) forecast of 0.2385 for the next financial year.

How can I tell whether the Ergomed share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ergomed. Over the past six months, the relative strength of its shares against the market has been 0.107k%. At the current price of 852p, shares in Ergomed are trading at 53.57% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Ergomed PE Ratio?

The Ergomed PE ratio based on its reported earnings over the past 12 months is 54.77. The shares are currently trading at 852p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Ergomed?

Ergomed's management team is headed by:

Miroslav Reljanovic - VCH
Terry Murdock - OTH
Chris Wilson - OTH
Branka Duvnjak - OTH
Danko Dominis - OTH
Michael Spiteri - NED
Richard Barfield - CFO
Rolf Soderstrom - NED
Ian Johnson - NED
Lewis Cameron - COO
Who are the major shareholders of Ergomed?

Here are the top five shareholders of Ergomed based on the size of their shareholding:

Reljanovic (Miroslav) Individual Investor
Percentage owned: 22.33% (10.9m shares)
Aberdeen Asset Managers Ltd. Investment Advisor/Hedge Fund
Percentage owned: 10.26% (5.00m shares)
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund
Percentage owned: 10.23% (4.98m shares)
Slater Investments Ltd. Investment Advisor/Hedge Fund
Percentage owned: 7.4% (3.60m shares)
Jupiter Asset Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 5.45% (2.66m shares)
Similar to ERGO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.